Qiagen (NYSE:QGEN) Shares Purchased by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC increased its stake in Qiagen (NYSE:QGEN) by 1.7% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 140,842 shares of the company’s stock after purchasing an additional 2,310 shares during the period. Segall Bryant & Hamill LLC owned 0.06% of Qiagen worth $6,418,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. Victory Capital Management Inc. raised its stake in Qiagen by 104,759.6% in the 2nd quarter. Victory Capital Management Inc. now owns 1,583,380 shares of the company’s stock worth $65,061,000 after acquiring an additional 1,581,870 shares during the last quarter. Earnest Partners LLC raised its stake in shares of Qiagen by 85.1% in the first quarter. Earnest Partners LLC now owns 3,427,605 shares of the company’s stock worth $147,353,000 after purchasing an additional 1,576,259 shares during the last quarter. Nuance Investments LLC lifted its holdings in shares of Qiagen by 17.3% during the second quarter. Nuance Investments LLC now owns 5,271,494 shares of the company’s stock worth $216,606,000 after purchasing an additional 778,005 shares during the period. Point72 Asset Management L.P. boosted its position in Qiagen by 148.8% in the second quarter. Point72 Asset Management L.P. now owns 1,184,806 shares of the company’s stock valued at $48,684,000 after buying an additional 708,533 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale increased its holdings in Qiagen by 12.2% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 3,248,354 shares of the company’s stock worth $133,292,000 after buying an additional 353,280 shares during the period. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Wall Street Analysts Forecast Growth

QGEN has been the topic of several recent research reports. Robert W. Baird upped their price objective on shares of Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. Hsbc Global Res raised Qiagen to a “hold” rating in a research report on Thursday, October 17th. Finally, HSBC cut Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price objective for the company. in a report on Thursday, October 17th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $50.88.

Qiagen Stock Performance

NYSE QGEN opened at $42.33 on Friday. The stock has a market capitalization of $9.66 billion, a price-to-earnings ratio of 108.54, a PEG ratio of 3.16 and a beta of 0.41. Qiagen has a twelve month low of $39.03 and a twelve month high of $47.44. The stock has a 50-day moving average of $43.57 and a 200 day moving average of $43.73. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.